Related Experiment Video
Updated: Nov 3, 2025
11:39
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
39.2K
Topical beta-blockers in dermatologic therapy
Angela Filoni1,2, Francesca Ambrogio1, Aurora De Marco1
1Section of Dermatology, Department of Biomedical Science and Human Oncology, University of Bari, Bari, Italy.
Dermatologic Therapy
|June 2, 2021
Summary
Topical beta-blockers are increasingly used in dermatology for various skin conditions beyond infantile hemangiomas. These treatments are proving safe and effective for conditions like pyogenic granuloma and Kaposi sarcoma, with minimal side effects.
Area of Science:
- Dermatology
- Pharmacology
Background:
- Beta-blockers are increasingly utilized in dermatological treatments.
- Their use for conditions other than infantile hemangiomas is often off-label.
Purpose of the Study:
- To review the emerging applications of topical beta-blockers in dermatology.
- To assess their efficacy and safety in treating various cutaneous diseases.
Main Methods:
- Literature review of studies on topical beta-blocker use in dermatology.
- Analysis of data regarding treatment of infantile hemangioma, pyogenic granuloma, Kaposi sarcoma, wounds, and nail paronychia.
Main Results:
- Topical beta-blockers demonstrate safety and efficacy across multiple dermatological conditions.
- Adverse effects are predominantly localized to the application site.
Conclusions:
- Topical beta-blockers represent a safe and effective therapeutic option for numerous skin diseases.
- Further research, including randomized trials, is needed to solidify their role in dermatological practice.
Related Concept Videos
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
1.2K
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.2K
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
842
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
842
01:28Antihypertensive Drugs: Types of β-Blockers
1.1K
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
1.1K
01:25Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
959
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
959
01:22Heart Failure Drugs: β-Blockers
538
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
538
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
1.1K
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
1.1K